The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease
- PMID: 33216025
- DOI: 10.3233/JAD-200578
The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease
Abstract
Background: Over 20 single-nucleotide polymorphisms (SNPs) are associated with increased risk of Alzheimer's disease (AD). We categorized these loci into immunity, lipid metabolism, and endocytosis pathways, and associated the polygenic risk scores (PRS) calculated, with AD biomarkers in mild cognitive impairment (MCI) subjects.
Objective: The aim of this study was to identify associations between pathway-specific PRS and AD biomarkers in patients with MCI and healthy controls.
Methods: AD biomarkers ([18F]Florbetapir-PET SUVR, FDG-PET SUVR, hippocampal volume, CSF tau and amyloid-β levels) and neurocognitive tests scores were obtained in 258 healthy controls and 451 MCI subjects from the ADNI dataset at baseline and at 24-month follow up. Pathway-related (immunity, lipid metabolism, and endocytosis) and total polygenic risk scores were calculated from 20 SNPs. Multiple linear regression analysis was used to test predictive value of the polygenic risk scores over longitudinal biomarker and cognitive changes.
Results: Higher immune risk score was associated with worse cognitive measures and reduced glucose metabolism. Higher lipid risk score was associated with increased amyloid deposition and cortical hypometabolism. Total, immune, and lipid scores were associated with significant changes in cognitive measures, amyloid deposition, and brain metabolism.
Conclusion: Polygenic risk scores highlights the influence of specific genes on amyloid-dependent and independent pathways; and these pathways could be differentially influenced by lipid and immune scores respectively.
Keywords: Alzheimer’s disease; SNPs; biomarkers; genetic risk; polygenic score.
Similar articles
-
Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging.Neuroimage Clin. 2019;22:101771. doi: 10.1016/j.nicl.2019.101771. Epub 2019 Mar 13. Neuroimage Clin. 2019. PMID: 30927601 Free PMC article.
-
Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.PLoS One. 2013 Jun 14;8(6):e66877. doi: 10.1371/journal.pone.0066877. Print 2013. PLoS One. 2013. PMID: 23799136 Free PMC article.
-
Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.J Alzheimers Dis. 2018;62(1):399-408. doi: 10.3233/JAD-170833. J Alzheimers Dis. 2018. PMID: 29439345
-
From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review.J Alzheimers Dis. 2020;74(4):1271-1283. doi: 10.3233/JAD-191233. J Alzheimers Dis. 2020. PMID: 32250305 Free PMC article.
-
The prognostic value of amyloid imaging.Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1207-19. doi: 10.1007/s00259-012-2108-x. Epub 2012 Apr 11. Eur J Nucl Med Mol Imaging. 2012. PMID: 22491780 Review.
Cited by
-
An opinion on the debatable function of brain resident immune protein, T-cell receptor beta subunit in the central nervous system.IBRO Neurosci Rep. 2022 Sep 6;13:235-242. doi: 10.1016/j.ibneur.2022.09.003. eCollection 2022 Dec. IBRO Neurosci Rep. 2022. PMID: 36590097 Free PMC article.
-
Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes.Glia. 2022 Feb;70(2):239-255. doi: 10.1002/glia.24096. Epub 2021 Sep 24. Glia. 2022. PMID: 34558120 Free PMC article. Review.
-
Alzheimer's disease and its treatment-yesterday, today, and tomorrow.Front Pharmacol. 2024 May 24;15:1399121. doi: 10.3389/fphar.2024.1399121. eCollection 2024. Front Pharmacol. 2024. PMID: 38868666 Free PMC article. Review.
-
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12. Alzheimers Dement. 2024. PMID: 37698424 Free PMC article. Review.
-
Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer's disease.Cell Rep Med. 2024 Sep 17;5(9):101735. doi: 10.1016/j.xcrm.2024.101735. Cell Rep Med. 2024. PMID: 39293391 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- MR/K013041/1/MRC_/Medical Research Council/United Kingdom
- G0300429/MRC_/Medical Research Council/United Kingdom
- U01 AG024904/AG/NIA NIH HHS/United States
- G0902227/MRC_/Medical Research Council/United Kingdom
- MR/L501517/1/MRC_/Medical Research Council/United Kingdom
- MC_PC_17112/MRC_/Medical Research Council/United Kingdom
- G0600237/MRC_/Medical Research Council/United Kingdom
- G9810900/MRC_/Medical Research Council/United Kingdom
- MR/M009076/1/MRC_/Medical Research Council/United Kingdom
- G0801418/MRC_/Medical Research Council/United Kingdom
- MR/L023784/2/MRC_/Medical Research Council/United Kingdom
- MR/L010305/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical